Medical and Science
MAPA announces leadership transition
The Medical Affairs Professionals of Australasia (MAPA) has announced leadership transition as it continues to build momentum in 2025. Lauren […]
MoreMedical and Science
Beyond the protocol: How Icon Group is redefining clinical trials with heart
Sophie Mepham, Group Executive Manager of Research at Icon Group, invites us into the often unseen world where purpose and […]
MoreMedical and Science
World’s largest study to decode genetic roots of eating disorders
Researchers from QIMR Berghofer and the InsideOut Institute have launched the world’s largest genetic study into eating disorders, calling on […]
MoreMedical and Science
What powers GenesisCare’s bold path in cancer research: Clinical Trials Day
What does it take to deliver research that truly changes lives? For Sonya McColl, National Research Manager of Oncology at […]
MoreMedical and Science
Health and medical research at a crossroads: Sector calls for reform as 48th Parliament takes shape
Australia’s 48th Parliament opens the door to a generational shift in how the nation approaches research and development, beckoning reforms […]
MoreMedical and Science
Major political parties dismiss research sector warnings
Australia’s major political parties have failed to commit to critical reforms that could determine the survival of the nation’s health […]
MoreMedical and Science
The high cost of record low research funding
Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]
MoreMedical and Science
MTAA and ARCS welcome Innovation Blueprint
The NSW Government has unveiled the NSW Innovation Blueprint 2035, a strategic plan designed to solidify the state’s position as […]
MoreMedical and Science
Research on life support as government Budget fails to deliver critical funding
Stakeholders are voicing disappointment over the government’s Budget failure to at least maintain research funding in line with inflation. In […]
MoreMedical and Science
Political interference in Australian research rejected by universities
The federal government has been strongly urged to reject the Trump administration’s attempts to influence Australian research projects. Researchers involved […]
MoreRecent Posts in Pharma, MedTech & Biotech
Philips remote monitoring cuts hospital costs and ICU time by 69%
August 1, 2025
in News - MedTech & Diagnostics
VB Spine breaks ground in ANZ, Takes over Stryker’s spinal implants business
August 1, 2025
in News - MedTech & Diagnostics
New therapy PBS listed in advanced Parkinson’s disease
August 1, 2025
in News - Pharmaceuticals
PBS adds first ustekinumab and omalizumab biosimilars in inflammatory and allergic conditions
August 1, 2025
in News - Pharmaceuticals
November PBAC agenda unveiled amid tensions over tariff risks
July 31, 2025
in News - Pharmaceuticals
Promises, pitfalls and pressure points: Stakeholders weigh in on government’s AI healthcare report
July 31, 2025
in News - MedTech & Diagnostics
MSAC to consider funding for first TGA-approved TTVR device
July 31, 2025
in News - MedTech & Diagnostics
The triple squeeze on leaders and a messy middle: New future of work report
July 30, 2025
in Leadership & Management
Follow Us
Partner with us
News - MedTech & Diagnostics
Philips remote monitoring cuts hospital costs and ICU time by 69%
An innovative remote patient monitoring model has significantly improved post-operative care for patients, cutting ICU hours by 69% and saving […]
MoreNews - MedTech & Diagnostics
VB Spine breaks ground in ANZ, Takes over Stryker’s spinal implants business
VB Spine has officially taken the reins of Stryker’s spinal implants business in Australia and New Zealand. The transition builds […]
MoreNews - Pharmaceuticals
New therapy PBS listed in advanced Parkinson’s disease
A new therapeutic option for advanced Parkinson’s disease, Vyalev (foslevodopa with foscarbidopa), is now listed on the Pharmaceutical Benefits Scheme […]
MoreNews - Pharmaceuticals
PBS adds first ustekinumab and omalizumab biosimilars in inflammatory and allergic conditions
From 1 August 2025, two new biosimilars – SteQeyma (ustekinumab) and Omlyclo (omalizumab) – have been listed on the Pharmaceutical […]
More